Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Johnson & Johnson (NY: JNJ )

153.31 +1.49 (+0.98%)
Official Closing Price Updated: 7:00 PM EDT, Mar 29, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 6,012,034
Open 152.24
Bid (Size) 152.00 (2)
Ask (Size) 153.76 (3)
Prev. Close 151.82
Today's Range 152.07 - 153.38
52wk Range 150.11 - 186.69
Shares Outstanding 2,628,679,824
Dividend Yield 2.64%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Johnson & Johnson Pulls Plug On Large Late-Stage Study Of RSV Vaccine Candidate; GSK, Pfizer Shots Are Under FDA Review
 
Via Benzinga
J&J Drops Out Of A Key Race, Leaving Pfizer, GSK, Moderna To Duke It Out
The company says it's refocusing its portfolio to focus on transformational medicines. 
Via Investor's Business Daily

Performance

YTD
-13.96%
-13.96%
1 Month
-1.49%
-1.49%
3 Month
-13.22%
-13.22%
6 Month
-7.84%
-7.84%
1 Year
-13.74%
-13.74%

More News

Read More
Benzinga's Top Ratings Upgrades, Downgrades For March 29, 2023
Via Benzinga
Analyst Expectations for Johnson & Johnson's Future
Via Benzinga
Johnson & Johnson Unusual Options Activity
Via Benzinga
Better Buy: AbbVie vs. Johnson & Johnson
Via The Motley Fool
Got $5,000? These 2 Blue Chip Stocks Are Near Multi-Year Lows
Via The Motley Fool
Is It Time to Buy the Dow Jones' 3 Worst-Performing Stocks This Year?
Via The Motley Fool
Top 5 "Forever" Stocks To Buy In 2023
Via Talk Markets
7 Dividend Aristocrats to Buy for Consistent Income Growth
Via InvestorPlace
Baby Health and Personal Care Market May See a Big Move : Johnson & Johnson, Danone, Pigeon
Via SBWire
Exposures Textiles
Looking At Johnson & Johnson's Recent Unusual Options Activity
Via Benzinga
Could This Drug Candidate Be a Winner for These 2 Big Pharma Stocks?
Via The Motley Fool
It's a Mistake to Ignore the Growth Potential of These 3 Dividend Stocks
Via The Motley Fool
3 Blue-Chip Stocks to Buy for Stability and Safety
Via InvestorPlace
Impact Biomedical Preparing A Potential Spinoff — What Does This Mean For Investors Of Holding Company DSS, Inc (NYSE American: DSS)?
Via Benzinga
Study Shows 186 Banks Are On The Brink Of Failure
Via Talk Markets
New Regional Director for EMEA to Drive Next Stage of Growth Across the Region for Jeron Nurse Call Systems
Via PRLog
Topics Economy
Exposures Supply Chain
Binance Suspends Trading, European Bank Trouble, Twitter To Remove Legacy Verified Checkmarks: Today's Top Stories
Via Benzinga
Johnson & Johnson Loses Key Tuberculosis Drug Patent In India, Makes Way For Domestic Generic Players
Via Benzinga
Have $1,000? 2 Smart Stocks to Buy This Month
Via The Motley Fool
3 Safe Dow Dividend Stocks to Buy Now
Via The Motley Fool
Think the Bear Market Is Over? Here's How to Invest $5,000
Via The Motley Fool
What Is Autologous Cell-Based Therapy, The Treatment Revolutionizing Regenerative Medicine That Could Be Set To Explode Over The Next Few Years?
Via TheNewswire.com
Exposures Product Safety
What Is Autologous Cell-Based Therapy, The Treatment Revolutionizing Regenerative Medicine That Could Be Set To Explode Over The Next Few Years?
Via News Direct
Exposures Product Safety
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.